June 19, 2017 / 8:12 AM / a month ago

BRIEF-Glepaglutide meets primary endpoint in Phase 2 trial

1 Min Read

June 19 (Reuters) - ZEALAND PHARMA A/S

* REG-GLEPAGLUTIDE MEETS PRIMARY ENDPOINT IN PHASE 2 TRIAL IN PATIENTS WITH SHORT BOWEL SYNDROME

* ‍POSITIVE RESULTS FROM PHASE 2 TRIAL OF GLEPAGLUTIDE IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below